A Phase I, Open Label, Dose Escalation Study of Immunoconjugate L-DOS47 in Combination with Standard Doublet Therapy of Pemetrexed/Carboplatin in Patients with Stage IV (TNM M1a and M1b) Recurrent or Metastatic Non-Squamous Non-Small Cell Lung Cancer ("NSCLC")

Trial Profile

A Phase I, Open Label, Dose Escalation Study of Immunoconjugate L-DOS47 in Combination with Standard Doublet Therapy of Pemetrexed/Carboplatin in Patients with Stage IV (TNM M1a and M1b) Recurrent or Metastatic Non-Squamous Non-Small Cell Lung Cancer ("NSCLC")

Recruiting
Phase of Trial: Phase I

Latest Information Update: 10 Apr 2018

At a glance

  • Drugs L-DOS 47 (Primary) ; Carboplatin; Pemetrexed
  • Indications Non-small cell lung cancer
  • Focus Adverse reactions
  • Sponsors Helix BioPharma
  • Most Recent Events

    • 10 Apr 2018 According to a Helix BioPharma media release, 9 patients have been dosed in this trial till date.
    • 19 Mar 2018 According to a Helix BioPharma media release, this clinical study has been facing patient enrolment challenges and as a result the company most recently increased start-up activities to add 6 additional clinical study sites, with planned recruitment to begin spring 2018.
    • 23 Feb 2018 According to a Helix BioPharma media release, the study will be presented at the IASLC 18th Annual Targeted Therapies of Lung Cancer Meeting at Santa Monica, California.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top